» Hämatologische Neoplasien » Verschiedene Neoplasien
Alle Linien
IMbrella B An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) (Aktiv)
LCH-REG-DE 2013 Deutsches Register für LCH im Kindes- und Jugendalter (Aktiv)
APEX A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (Aktiv)
Bayer 18117 An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 (Aktiv)
CLDK378A2407 study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)
Carlotta01 A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA- targeting CAR T-cells in patients with relapsed and refractory B-cell malignancies CARLOTTA01 (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
HD-CAR-1/V03 Treatment of patients with CD19+ hematologic disease with T lymphocytes transduced retrovirally with a third generation CAR (Aktiv)
Prothena NEOD001-301- AFFIRM-AL (#1367) A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis (Aktiv)